The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 23% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (10 analysts) rates it buy, with a mean price target of $162. It reported earnings in this window, a natural checkpoint for the thesis.
HSBC Holdings plc 0005.HK
Outside both standardsAn entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · HSBC Holdings plc engages in the provision of banking and financial products and services worldwide.
read at $162.10
HSBC Holdings plc holds its Accumulation at $162.10.
- PHPhase · the trend structure carries the Accumulation label
- INInsiders · no filings inside 60 days, left as found
- POPositioning · no disclosures inside 60 days, left as found
- OPOptions · no verdict drawn today, left as found
- SCScreen · does not pass the values gate
- edge confirmed
- edge broken
- edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
The investor read · the season, not the day
| Phase | Accumulation |
| Quantitative state | Consolidating, no directional conviction, held for 15 days |
| Price | $162.10 |
| Valuation | 14.78 trailing · 11.22 forward price to earnings |
| Values screen | FAIL |
| Beta | 0.58 |
The opportunity · what the numbers say it is worth
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
| Revenue growth | 3.30% |
| Profit margin | 34.98% |
| Analyst consensus | Buy · 10 covering |
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
The values screen, explained · five checks, plain English
This company is excluded by both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. It fails on both:
Used by most halal investing apps ✗ DOES NOT PASS
The one Titan applies ✗ DOES NOT PASS
Why it fails. The problem is its business activity: conventional financial services (interest-based). Because both standards agree on this, it is a clear exclusion, not a borderline case.
What these two standards are, and how they differ →
- Business activity Its core business involves an activity the values screen does not clear. Fail
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
The business, in plain words · what the numbers mean
| Forward P/E | 11.2x expensive even after accounting for its growth |
| Trailing P/E | 14.8x reasonably valued |
| Revenue growth | 3.3% slow but positive growth |
| Profit margin | 35.0% highly profitable on every dollar of sales |
| Return on equity | 11.6% a modest return on shareholder capital |
| Beta | 0.58 steadier than the market |
| Market cap | $2.78T |
The risks · The things to watch: its business and earnings are exposed to United Kingdom and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Latest news · what the market is reading on 0005.HK
- › Cisco rating cut at HSBC as analyst sees a lack of catalysts Investing.com · 1d ago
- › Businesses Are Spending Big on Quantum The Wall Street Journal · 2d ago
- › Why Cognex (CGNX) Shares Are Sliding Today StockStory · 3d ago
- › HSBC Just Downgraded Akamai Technologies Stock. Here’s Why. Barchart · 3d ago
- › China Earnings to Test Rotation From AI to Internet Stocks Bloomberg · 4d ago
Headlines from third-party outlets, linked for reference — not our reporting, not advice.
Related securities · others in 0005.HK's space worth a look
Screened names in the same industry · explore each on its own page.
The trader read · the latest dated commentary
The dated journal · newest first, never edited
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 23% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (10 analysts) rates it buy, with a mean price target of $162. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 23% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (10 analysts) rates it buy, with a mean price target of $162. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 23% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (10 analysts) rates it buy, with a mean price target of $162. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 23% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (10 analysts) rates it buy, with a mean price target of $162. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 23% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (10 analysts) rates it buy, with a mean price target of $162. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.9% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 23% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (10 analysts) rates it buy, with a mean price target of $162. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 10.3% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 23% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (10 analysts) rates it buy, with a mean price target of $162.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 23% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 50%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (10 analysts) rates it buy, with a mean price target of $162.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
What holding actually paid · price plus dividends
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $141.10 | -4.1% | $0.78 | $964 | -3.6% |
| 2 months | $139.60 | -3.1% | $0.78 | $975 | -2.5% |
| 3 months | $128.81 | +5.0% | $4.31 | $1,084 | +8.4% |
| 6 months | $114.11 | +18.6% | $4.31 | $1,223 | +22.3% |
| 1 year | $89.95 | +50.4% | $5.86 | $1,569 | +56.9% |
| 2 years | $61.89 | +118.6% | $10.99 | $2,364 | +136.4% |
| 3 years | $48.79 | +177.3% | $17.40 | $3,130 | +213.0% |
| 5 years | $35.05 | +286.0% | $22.65 | $4,506 | +350.6% |
Historical returns from market close data. Past performance does not guarantee future results.